Please login to the form below

Not currently logged in
Email:
Password:

Lothian pharmacies off cessation target

A strategy by NHS Lothian to move much of its smoking cessation services into pharmacies is well behind schedule

A strategy by NHS Lothian - one of the 15 regions of NHS Scotland - to move much of its region's smoking cessation services into pharmacies is well behind schedule on its targets, according to a presentation to the NHS Lothian board members by lead officers Mike Massarro-Mallinson and Fiona Hume.

Massarro-Mallinson and Hume explained that while it had been anticipated that pharmacies would deliver 40 per cent of the target, to date they have only contributed 8 per cent of successful outcomes achieved. 

This is despite a series of measures being outlined to make it happen, such as one-to-one help for quitters who are a month into kicking their habit, a significant advertising campaign signposting that the pharmacy scheme is underway and a pilot scheme which sees city chemists offer impromptu check-ups for harassed commuters.

Following these recent findings, the Lothian health board has vowed to provide extra training to community pharmacy staff in a bid to improve their skills in smoking cessation support and heed NHS Scotland's recent call to local health chiefs to obtain 11,000 successful quitters by 2011.

Despite the poor return from pharmacies however, 44 per cent more people attempted to stop smoking in the Lothians with the help of medics last year than the figures for 2007 reveal.

22nd June 2009

From: Healthcare

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
certain health

Transforming the way health brands and companies communicate, we deliver creative science led, insight-driven solutions that give award winning results...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...